The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Steven Claes - One of the best experts on this subject based on the ideXlab platform.

  • structural allograft impaction enables fast rehabilitation in opening wedge high tibial osteotomy a Consecutive Case Series with one year follow up
    Knee Surgery Sports Traumatology Arthroscopy, 2020
    Co-Authors: Wouter Van Genechten, Maxim Van Den Bempt, Wouter Van Tilborg, Stijn Bartholomeeusen, Gert Van Den Bogaert, Toon Claes, Steven Claes
    Abstract:

    Purpose Painful and slow recovery are the presumed disadvantages after opening-wedge high tibial osteotomy (HTO) and play a role in favouring arthroplasty as treatment for moderate isolated medial knee arthritis. The primary study objective was to investigate the effect of press-fit structural impacted bone allograft with locking plate fixation on early ambulation, postoperative pain levels, and resumption of daily-life activities in opening-wedge HTO.

  • structural allograft impaction enables fast rehabilitation in opening wedge high tibial osteotomy a Consecutive Case Series with one year follow up
    Knee Surgery Sports Traumatology Arthroscopy, 2020
    Co-Authors: Wouter Van Genechten, Maxim Van Den Bempt, Wouter Van Tilborg, Stijn Bartholomeeusen, Gert Van Den Bogaert, Toon Claes, Steven Claes
    Abstract:

    Painful and slow recovery are the presumed disadvantages after opening-wedge high tibial osteotomy (HTO) and play a role in favouring arthroplasty as treatment for moderate isolated medial knee arthritis. The primary study objective was to investigate the effect of press-fit structural impacted bone allograft with locking plate fixation on early ambulation, postoperative pain levels, and resumption of daily-life activities in opening-wedge HTO. A prospective Consecutive opening-wedge HTO Case Series was conducted, including 103 patients with final follow-up at 1 year. Weight-bearing was allowed from the day after surgery “as tolerated” by the patient. Clinical assessment included the Numeric Rating Scale (NRS), Knee injury and Osteoarthritis Outcome Score (KOOS), and Lysholm score. Additionally, the Knee Society Score (KSS) was assessed during consultation at 1, 3, and 12 months postoperatively with special attention for clinical anchor questions. Required sample size was calculated and a linear mixed-effect model was used for repeated measures over time of the clinical scores. The NRS decreased by 1.5 at 1 month (p   500 m without support, while all patients were able to climb up and down the stairs 3 months postoperatively. The study strongly supports the initial hypothesis that applying structural triangular bone allograft in HTO leads to low postoperative pain levels, early ambulation, and excellent short-term clinical outcomes. Study results have the potential to alter the general perception about HTO being a painful procedure with painstakingly slow recovery and consequently encourage the consideration of HTO as a highly valuable joint-preserving option, while treating unicompartmental knee arthritis. IV (Case Series).

Giancarlo Pruneri - One of the best experts on this subject based on the ideXlab platform.

  • estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer a retrospective Consecutive Case Series
    International Journal of Clinical Oncology, 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, F Nole, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri
    Abstract:

    Background Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease.

  • estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer a retrospective Consecutive Case Series
    International Journal of Clinical Oncology, 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, F Nole, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri
    Abstract:

    Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease. EMP was given orally at a dose of 140 mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five Cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12 months were 39 and 8 %, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug.

  • Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer : a retrospective Consecutive Case Series
    'Springer Science and Business Media LLC', 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri, F. Nol&#232, A. Goldhirsch
    Abstract:

    Background: Estramustine phosphate sodium (EMP) is an oral agent poorly developed\u2014although active\u2014in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease. Methods: EMP was given orally at a dose of 140 mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Results: Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five Cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12 months were 39 and 8 %, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Conclusion: Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug

Vincenzo Bagnardi - One of the best experts on this subject based on the ideXlab platform.

  • estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer a retrospective Consecutive Case Series
    International Journal of Clinical Oncology, 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, F Nole, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri
    Abstract:

    Background Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease.

  • estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer a retrospective Consecutive Case Series
    International Journal of Clinical Oncology, 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, F Nole, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri
    Abstract:

    Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease. EMP was given orally at a dose of 140 mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five Cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12 months were 39 and 8 %, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug.

  • Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer : a retrospective Consecutive Case Series
    'Springer Science and Business Media LLC', 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri, F. Nol&#232, A. Goldhirsch
    Abstract:

    Background: Estramustine phosphate sodium (EMP) is an oral agent poorly developed\u2014although active\u2014in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease. Methods: EMP was given orally at a dose of 140 mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Results: Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five Cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12 months were 39 and 8 %, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Conclusion: Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug

Wouter Van Genechten - One of the best experts on this subject based on the ideXlab platform.

  • structural allograft impaction enables fast rehabilitation in opening wedge high tibial osteotomy a Consecutive Case Series with one year follow up
    Knee Surgery Sports Traumatology Arthroscopy, 2020
    Co-Authors: Wouter Van Genechten, Maxim Van Den Bempt, Wouter Van Tilborg, Stijn Bartholomeeusen, Gert Van Den Bogaert, Toon Claes, Steven Claes
    Abstract:

    Purpose Painful and slow recovery are the presumed disadvantages after opening-wedge high tibial osteotomy (HTO) and play a role in favouring arthroplasty as treatment for moderate isolated medial knee arthritis. The primary study objective was to investigate the effect of press-fit structural impacted bone allograft with locking plate fixation on early ambulation, postoperative pain levels, and resumption of daily-life activities in opening-wedge HTO.

  • structural allograft impaction enables fast rehabilitation in opening wedge high tibial osteotomy a Consecutive Case Series with one year follow up
    Knee Surgery Sports Traumatology Arthroscopy, 2020
    Co-Authors: Wouter Van Genechten, Maxim Van Den Bempt, Wouter Van Tilborg, Stijn Bartholomeeusen, Gert Van Den Bogaert, Toon Claes, Steven Claes
    Abstract:

    Painful and slow recovery are the presumed disadvantages after opening-wedge high tibial osteotomy (HTO) and play a role in favouring arthroplasty as treatment for moderate isolated medial knee arthritis. The primary study objective was to investigate the effect of press-fit structural impacted bone allograft with locking plate fixation on early ambulation, postoperative pain levels, and resumption of daily-life activities in opening-wedge HTO. A prospective Consecutive opening-wedge HTO Case Series was conducted, including 103 patients with final follow-up at 1 year. Weight-bearing was allowed from the day after surgery “as tolerated” by the patient. Clinical assessment included the Numeric Rating Scale (NRS), Knee injury and Osteoarthritis Outcome Score (KOOS), and Lysholm score. Additionally, the Knee Society Score (KSS) was assessed during consultation at 1, 3, and 12 months postoperatively with special attention for clinical anchor questions. Required sample size was calculated and a linear mixed-effect model was used for repeated measures over time of the clinical scores. The NRS decreased by 1.5 at 1 month (p   500 m without support, while all patients were able to climb up and down the stairs 3 months postoperatively. The study strongly supports the initial hypothesis that applying structural triangular bone allograft in HTO leads to low postoperative pain levels, early ambulation, and excellent short-term clinical outcomes. Study results have the potential to alter the general perception about HTO being a painful procedure with painstakingly slow recovery and consequently encourage the consideration of HTO as a highly valuable joint-preserving option, while treating unicompartmental knee arthritis. IV (Case Series).

Gaetano Aurilio - One of the best experts on this subject based on the ideXlab platform.

  • estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer a retrospective Consecutive Case Series
    International Journal of Clinical Oncology, 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, F Nole, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri
    Abstract:

    Background Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease.

  • estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer a retrospective Consecutive Case Series
    International Journal of Clinical Oncology, 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, F Nole, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri
    Abstract:

    Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease. EMP was given orally at a dose of 140 mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five Cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12 months were 39 and 8 %, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug.

  • Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer : a retrospective Consecutive Case Series
    'Springer Science and Business Media LLC', 2015
    Co-Authors: Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri, F. Nol&#232, A. Goldhirsch
    Abstract:

    Background: Estramustine phosphate sodium (EMP) is an oral agent poorly developed\u2014although active\u2014in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective Series of Consecutive patients with estrogen receptor-positive disease. Methods: EMP was given orally at a dose of 140 mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Results: Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five Cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12 months were 39 and 8 %, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Conclusion: Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug